Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214311 · ClinicalTrials.gov registry record · Phase 2
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
A Phase 2 study of Prosthetic-joint Infection, sponsored by Peptilogics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 7
- Study locations
NCT07214311: Recruiting Phase 2 study of Prosthetic-joint Infection, sponsored by Peptilogics.
NCT07214311 is a Phase 2 study of Prosthetic-joint Infection that is actively recruiting participants, run by Peptilogics. The registered enrollment target is 240 participants, above the 72-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (233% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214311, a Phase 2 study of Prosthetic-joint Infection, is actively recruiting participants, sponsored by Peptilogics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.
Primary Outcome
Proportion of participants with PJI treatment failure following DAIR
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PLG0206
Study Locations (7)
Florida
- Clinical Trial Site - Sarasota
- Clinical Trial Site - Tamarac
Ohio
- Clinical Trial Site - Cincinnati
- Clinical Trial Site - Columbus
Maryland
- Clinical Trial Site - Baltimore
Massachusetts
- Clinical Trial Site - Boston
West Virginia
- Clinical Trial Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What NCT07214311 shows while recruiting
NCT07214311 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 72-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (233% higher).
The record links to 1 condition, with Prosthetic-joint Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07214311 lists 7 locations in 5 states (Florida, Ohio, Maryland).
Frequently Asked Questions
What is clinical trial NCT07214311 about?
NCT07214311 is a clinical study titled "Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty". The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Join...
What is the current status of trial NCT07214311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-02-03. Estimated completion is 2028-09.
What conditions does trial NCT07214311 study?
This clinical trial studies the following conditions: Prosthetic-joint Infection.
What interventions are being tested in trial NCT07214311?
The interventions under investigation include: Placebo (DRUG), PLG0206 (DRUG).
Who is sponsoring clinical trial NCT07214311?
This trial is sponsored by Peptilogics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214311 being conducted?
This trial has 7 study locations across Florida, Maryland, Massachusetts, Ohio, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prosthetic-joint Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07214311's enrollment target sits among peer trials
240 1st of 9 higher than 9 of 9 other Prosthetic-joint Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prosthetic-joint Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Second Trial of the Abbreviated Protocol Two-Stage Exchange
COMPLETED · Phase 2
-
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
COMPLETED · Phase 2
-
The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee
RECRUITING · NA
-
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
RECRUITING · NA
-
Reduction of Bacterial Seeding in Total Shoulder Arthroplasty
RECRUITING · NA
-
SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI